The first pharmaceutical company to reach a market capitalization of $1.3 trillion isn’t selling a story.
Eli Lilly’s third-quarter revenue was $24.397 billion, up 39% year over year. Mounjaro brought in $10.723 billion for the quarter, up 65%, and Zepbound $5.352 billion, up 49%. Its full-year revenue guidance was raised for the third time this year, to $91–92 billion. The stock surged more than 9% intraday at one point, hitting a record high.
$LLY Repeat purchases of pills turn into cash sooner than orders for computing power.
Eli Lilly’s third-quarter revenue was $24.397 billion, up 39% year over year. Mounjaro brought in $10.723 billion for the quarter, up 65%, and Zepbound $5.352 billion, up 49%. Its full-year revenue guidance was raised for the third time this year, to $91–92 billion. The stock surged more than 9% intraday at one point, hitting a record high.
$LLY Repeat purchases of pills turn into cash sooner than orders for computing power.
